Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Do you know how much you can sell 17,000 barrels of oil for?
The website has had a make over ! It looks much more attractive !
A combined test could be very powerful. There is currently an incidence of Covid in the UK population of 0.05% (1 in 2000). We are assured that the specificity of our LFT test is very high. The most pessimistic sensitivity figure for LFT tests that I've seen is 50%. and I think a reasonable interpretation of 'highly specific' is 98%. If you take a test group of 10,000 people these figures produce a set of approx 200 positive results. These could be quarantined and retested using PCR - probably within 48 hours or less.
It's a method of applying coarse and fine filters. The coarse (highly specific) filter enables 9,800 people to go back to work. It will identify 2.5 true positives and miss 2.5 . However being able to exclude 50% of truly infected people from the population could take the R number below the critical value of 1.
I think the CEO has indicated that the sensitivity is much higher than 50% but even at that low level the LFT could be very effective.
I agree that it is easily fixed. The fact that it hasn't been fixed points to lack luster management. I'm not inspired by the company but the cost savings from the prepack admin are very substantial and they recovered very strongly from exactly the same situation in 2008.
They did another prepack back in 2008/9 after which the business was very successful resulting in the IPO in 2017 . Paul Scott on Stockopedia has written a very insightful piece and rates Quiz as high risk with the a real potential to multibag. Stocko isn't cheap but it has paid for itself every year that I've been a member.
Retail is recovering - a recent report said that is 3% up on last year but the lead is being taken by online retail for as we all know, the high street is suffering badly. For that reason I'm very interested in online retail. My man reservation with Quiz is that if you compare its website with Sosandar it looks a bit amateurish whereas Sosandar is vibrant and eye catching. One example is when you place your cursor on a dress it shows another view . Not rocket science but very useful I imagine when buying a dress. Long term I much prefer Sosandar.
By the way, I'm not interested in BooHoo as it is already on an astronomical valuation.
Her second point seems to be that only big pharma have the infrastructure to get a newly approved drug to market and SNG is too small to do it on their own. Perhaps she hadn't read this on SNG's website :
"Since the outbreak of COVID-19, Synairgen has been approached by, and is in discussion with, a number of other medical, scientific, and Governmental bodies (both in the UK, US and internationally) seeking to investigate novel therapeutics in this area."
Synairgen's treatment replaces a deficiency in a protein (Interferon beta) which is already produced by the lungs in response to the virus. Injectable interferon beta is already approved as a medicine and is in use. This leads me to believe that we have a head start in the race to approvals.
The central point of the MF article is that Phase 3 trials can take a very long time. The company has said that they intend to develop SNG001 as rapidly as possible and I tend to believe them.
Distribution agreements are not sales. I am minded of Fox Marble which periodically publishes memorandums of understanding generating a flurry of interest but has been in steady decline for years.
No one has produced a reason for today's spectacular rise. Someone mentioned anti viral properties but gave no reference and I have found none. All I can think of is the listing in the US where a lot of free money is looking for a home. Of course there may be news later today that graphene is the cure for cancer but right now I don't see it. Enjoy your profits !